Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | RAB9A, member RAS oncogene family | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | ATPase family, AAA domain containing 5 | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Homo sapiens | Niemann-Pick disease, type C1 | Starlite/ChEMBL | No references |
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Plasmodium falciparum | ras-related protein Rab-5B | RAB9A, member RAS oncogene family | 201 aa | 165 aa | 30.9 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 0.1007 | 0.6167 |
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 0.1007 | 0.6167 |
Schistosoma mansoni | amine oxidase | 0.0196 | 0.1007 | 0.1007 |
Echinococcus granulosus | lysine specific histone demethylase 1A | 0.0196 | 0.1007 | 0.1166 |
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | 0.0979 | 0.6464 | 0.6464 |
Brugia malayi | amine oxidase, flavin-containing family protein | 0.0196 | 0.1007 | 0.6167 |
Leishmania major | UDP-galactopyranose mutase | 0.0196 | 0.1007 | 0.5 |
Echinococcus multilocularis | protein dispatched 1 | 0.0058 | 0.005 | 0.005 |
Schistosoma mansoni | amine oxidase | 0.0196 | 0.1007 | 0.1007 |
Echinococcus granulosus | Niemann Pick C1 protein | 0.0119 | 0.0473 | 0.0547 |
Plasmodium falciparum | lysine-specific histone demethylase 1, putative | 0.0196 | 0.1007 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 0.1007 | 0.6167 |
Echinococcus granulosus | expressed conserved protein | 0.0112 | 0.0422 | 0.0489 |
Schistosoma mansoni | Lysine-specific histone demethylase 1 | 0.0196 | 0.1007 | 0.1007 |
Echinococcus multilocularis | lysine specific histone demethylase 1A | 0.0196 | 0.1007 | 0.1007 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.1633 | 0.1633 |
Echinococcus multilocularis | expressed conserved protein | 0.0112 | 0.0422 | 0.0422 |
Entamoeba histolytica | Niemann-Pick C1 protein, putative | 0.0119 | 0.0473 | 0.5 |
Echinococcus granulosus | Niemann Pick C1 protein | 0.017 | 0.0828 | 0.0959 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.1633 | 1 |
Echinococcus multilocularis | Niemann Pick C1 protein | 0.0119 | 0.0473 | 0.0473 |
Echinococcus multilocularis | Niemann Pick C1 protein | 0.017 | 0.0828 | 0.0828 |
Mycobacterium tuberculosis | Probable protoporphyrinogen oxidase HemY (protoporphyrinogen-IX oxidase) (protoporphyrinogenase) (PPO) | 0.1291 | 0.8637 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 0.1007 | 0.6167 |
Trypanosoma cruzi | UDP-galactopyranose mutase | 0.0196 | 0.1007 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0196 | 0.1007 | 0.5 |
Toxoplasma gondii | histone lysine-specific demethylase LSD1/BHC110/KDMA1A | 0.0196 | 0.1007 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 0.1007 | 0.6167 |
Echinococcus granulosus | protoporphyrinogen oxidase | 0.1291 | 0.8637 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0196 | 0.1007 | 0.5 |
Schistosoma mansoni | survival motor neuron protein | 0.0058 | 0.005 | 0.005 |
Schistosoma mansoni | niemann-pick C1 (NPC1) | 0.0121 | 0.0485 | 0.0485 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0.008 | 0.0489 |
Plasmodium vivax | lysine-specific histone demethylase 1, putative | 0.0196 | 0.1007 | 0.5 |
Brugia malayi | Niemann-Pick C1 protein precursor | 0.0119 | 0.0473 | 0.2894 |
Echinococcus multilocularis | 0.0196 | 0.1007 | 0.1007 | |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0278 | 0.1579 | 0.0749 |
Brugia malayi | SWIRM domain containing protein | 0.0196 | 0.1007 | 0.6167 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.1633 | 0.1891 |
Plasmodium falciparum | protoporphyrinogen oxidase | 0.0196 | 0.1007 | 0.5 |
Brugia malayi | hypothetical protein | 0.0196 | 0.1007 | 0.6167 |
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 0.1007 | 0.6167 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 0.0473 | 0.2894 |
Plasmodium vivax | protoporphyrinogen oxidase, putative | 0.0196 | 0.1007 | 0.5 |
Brugia malayi | Iron-sulfur cluster assembly accessory protein | 0.0058 | 0.005 | 0.0308 |
Trypanosoma cruzi | UDP-galactopyranose mutase | 0.0196 | 0.1007 | 0.5 |
Toxoplasma gondii | histone lysine-specific demethylase | 0.0196 | 0.1007 | 0.5 |
Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0196 | 0.1007 | 0.5 |
Onchocerca volvulus | 0.0196 | 0.1007 | 1 | |
Schistosoma mansoni | hypothetical protein | 0.0058 | 0.005 | 0.005 |
Brugia malayi | hypothetical protein | 0.0286 | 0.1633 | 1 |
Echinococcus granulosus | lysine specific histone demethylase 1A | 0.0196 | 0.1007 | 0.1166 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.7943 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 2.8184 um | PUBCHEM_BIOASSAY: qHTS Assay for NPC1 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 3.5481 um | PUBCHEM_BIOASSAY: qHTS Assay for Rab9 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.3535 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 16.5113 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 21.3313 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.